Ixabepilone and Carboplatin for Hormone Receptor Positive/HER2-neu Negative and Triple Negative Metastatic Breast Cancer von Osborne, Cynthia, Challagalla, Jagathi D., Eisenbeis, Charles F., Holmes, Frankie Ann, Neubauer, Marcus A., Koutrelakos, Nicholas W., Taboada, Carlos A., Vukelja, Sasha J., Wilks, Sharon T., Allison, Mary Ann, Reddy, Praveen, Sedlacek, Scot, Wang, Yunfei, Asmar, Lina, O’Shaughnessy, Joyce

Volltext

Durable Response to Crizotinib in a MET-Amplified, KRAS-Mutated Carcinoma of Unknown Primary von Palma, Norma A., Ali, Siraj M., O'Connor, Jamie, Dutta, Deepa, Wang, Kai, Soman, Salil, Palmer, Gary A., Morosini, Deborah, Ross, Jeffrey S., Lipson, Doron, Stephens, Phil J., Patel, Mayur, Miller, Vincent A., Koutrelakos, Nicholas

Volltext

Abstract PD7-10: Randomized, multicenter phase II trial of weekly paclitaxel with or without the oral selective aurora kinase A (AURKA) inhibitor, Alisertib, in patients with ER+ H... von O'Shaughnessy, Joyce, McIntyre, Kristi, Wilks, Sharon, Ma, Ling, Fintel, William, Block, Margaret, Andorsky, David, Danso, Michael, Koutrelakos, Nicholas, Locke, Tracy, Scales, Amy, Steckel, Lauren, Wang, Yunfei

Volltext

Phase II randomized trial of weekly and every-3-week ixabepilone in metastatic breast cancer patients von Smith, John W., Vukelja, Svetislava, Rabe, Amy, Wentworth-Hartung, Nicole, Koutrelakos, Nicholas, Shao, Spencer H., Whittaker, Thomas, Wang, Yunfei, Asmar, Lina, McDowell, Diane Opatt, Mukhopadhyay, Pralay, O’Shaughnessy, Joyce

Volltext

Durable Response to Crizotinib in a MET-Amplified, KRAS-Mutated Carcinoma of Unknown Primary von Palma, Norma A, Ali, Siraj M, O'Connor, Jamie, Dutta, Deepa, Wang, Kai, Soman, Salil, Palmer, Gary A, Morosini, Deborah, Ross, Jeffrey S, Lipson, Doron, Stephens, Phil J, Patel, Mayur, Miller, Vincent A, Koutrelakos, Nicholas

Volltext